832 results on '"Wechalekar, Ashutosh D."'
Search Results
2. Amyloid Light Chain (AL) Amyloidosis
3. Treatment of Amyloid Light-Chain Amyloidosis
4. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748
5. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
6. Extensive cardiac FDG uptake in a patient with AL amyloidosis
7. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis
8. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
9. Primary Light Chain (AL) Amyloidosis
10. Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime
11. Daratumumab in AL amyloidosis
12. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
13. AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review
14. Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
15. A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
16. High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
17. Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis
18. Wild-type transthyretin cardiac amyloidosis: When is a rare disease no longer a rare disease?
19. Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement.
20. Standardized reporting of monoclonal immunoglobulin–associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group
21. Recommendations for good clinical practice for DPD bone scintigraphy for cardiac amyloidosis
22. Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis
23. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
24. Systemic amyloidosis: moving into the spotlight
25. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
26. Deep phenotyping of p.(V142I)‐associated variant ATTR amyloid cardiomyopathy: distinct from wild‐type ATTR amyloidosis?
27. Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia
28. Myocardial Edema and Prognosis in Amyloidosis
29. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome
30. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
31. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
32. High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study
33. The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis
34. Deep phenotyping of p.(V142I)‐associated variant transthyretin amyloid cardiomyopathy: Distinct from wild‐type transthyretin amyloidosis?
35. Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia.
36. Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis.
37. Amyloidosis Diagnosed in Solid Organ Transplant Recipients
38. Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds
39. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis
40. Systemic amyloidosis
41. Natural history and outcome of light chain deposition disease
42. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis
43. A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis
44. Quality of Life and Symptoms Among Patients With Relapsed/Refractory AL Amyloidosis Treated With Ixazomib‐Dexamethasone Versus Physician's Choice
45. Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study
46. Role of imaging in cardiac amyloidosis: An ongoing challenge
47. Type 1 Cryoglobulinaemia Associated with Waldenström Macroglobulinemia, IgM MGUS or Non-Hodgkin Lymphoma
48. Low Toxicity and Disease Responses in Systemic AL-Amyloidosis Using an Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody TLX66 As the Only Conditioning Prior to Autologous Stem Cell Transplantation
49. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
50. Survey of the Relevance of Quality of Life (QoL) Questionnaires (QoLQs) Currently Used to Evaluate Multiple Myeloma (MM) Patients' Qol in Real-World MM Patients and Healthcare Professionals (HCPs)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.